Fairvalue-Calculator Fairvalue-Calculator
EN DE

Upstream Bio, Inc (UPB) Fair Value & Analysis

Healthcare · US · Market cap $344M

Price$6.35
Fair Value$6.21
Upside-2.2%
Quality91/100
Evidence: Low Range $4.10 – $7.76

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Upstream Bio, Inc (UPB) currently trades at $6.35, while our model-based Fair Value estimate is $6.21 — implying the stock looks roughly 2.2% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Upstream Bio, Inc (UPB) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.21 versus a price of $6.35 — about −2% (overvalued). Model-based estimate, not financial advice.
What is the fair value of UPB?
Our 21-model fair value for Upstream Bio, Inc is $6.21 (as of Jun 25, 2026), built from audited fundamentals. The current price is $6.35.
What is the quality score of UPB?
Upstream Bio, Inc has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.